Genprex, Inc. - Common Stock (GNPX)
0.2950
+0.0649 (28.21%)
NASDAQ · Last Trade: Apr 2nd, 5:26 PM EDT
Detailed Quote
Previous Close | 0.2301 |
---|---|
Open | 0.2400 |
Bid | 0.3810 |
Ask | 0.3954 |
Day's Range | 0.2400 - 0.3847 |
52 Week Range | 0.2200 - 4.090 |
Volume | 43,429,159 |
Market Cap | 17.53M |
PE Ratio (TTM) | -2.458 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,827,568 |
About Genprex, Inc. - Common Stock (GNPX)
Genprex Inc is a biotechnology company focused on developing innovative gene therapy treatments for cancer and diabetes. Their primary aim is to enhance the efficacy of existing therapies and improve patient outcomes through the use of their proprietary Oncoprex immunogene therapy, which targets various types of tumors. The company is dedicated to advancing its promising treatments through clinical trials and aims to address significant unmet medical needs in oncology. With a strong emphasis on research and development, Genprex seeks to create transformative therapies that can benefit patients and improve their quality of life. Read More
News & Press Releases
Via Benzinga · April 2, 2025
Via Benzinga · April 2, 2025
Via Benzinga · March 18, 2025

Via Benzinga · February 11, 2025

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.
Via Benzinga · November 4, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 24, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 16, 2024
Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
• Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes.
Via Get News · September 4, 2024
Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
• Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes in New Video Presentation.
Via Get News · August 22, 2024

Via Benzinga · August 13, 2024